Naglazyme is a solution for infusion (drip into a vein) that contains the active substance galsulfase (1 mg/ml).
|Table of Contents|
|What is it used for?|
|How is it used?|
|How does it work?|
|How has it been studied?|
|What benefits has it shown during the studies?|
|What is the risk associated?|
|Why has it been approved?|
Naglazyme is used to treat patients who have mucopolysaccharidosis VI (MPS VI or Maroteaux-Lamy syndrome). This disease is caused by the lack of an enzyme called N-acetylgalactosamine 4-sulfatase, which is needed to break down substances in the body called glycosaminoglycans (GAGs). If the enzyme is not present, GAGs cannot be broken down and they build up in the cells. This causes the signs of the disease, the most noticeable being a short body, a large head and difficulty moving about. The disease is usually diagnosed in infants between one and five years of age.
Because the number of patients with MPS VI is low, the disease is considered ?rare?, and Naglazyme was designated an ?orphan medicine? (a medicine used in rare diseases) on 14 February 2001.
The medicine can only be obtained with a prescription.
Naglazyme treatment should be supervised by a doctor who has experience in the management of patients with MPS VI or similar diseases. It should be given where resuscitation equipment is available in case of a medical emergency.
Naglazyme is given as a four-hour infusion once a week. The recommended dose is 1 mg per kilogram bodyweight. Before each infusion, patients should be given an antihistamine to reduce the risk of an allergic reaction. Patients may also be given a medicine to prevent fever.
Naglazyme is an enzyme replacement therapy. Enzyme replacement therapy provides patients with the enzyme they are lacking. The active substance in Naglazyme, galsulfase, is a copy of the human enzyme N-acetylgalactosamine 4-sulfatase. Naglazyme helps to break down the GAGs and stop them building up in the cells. This can improve the symptoms of MPS VI, including the ability of patients to move about.
Galsulfase is produced by a method known as ?recombinant DNA technology?: it is made by a cell that has received a gene (DNA), which makes it able to produce the enzyme.
Naglazyme has been compared with placebo (a dummy treatment) in one main study involving 39 patients with MPS VI aged between five and 29 years. The main measure of effectiveness was how far the patients could walk after 24 weeks of treatment.
Naglazyme was more effective than placebo. After 24 weeks, the average distance walked over 12 minutes increased by 109 metres in the patients treated with Naglazyme and by 18 metres in those receiving placebo.
In studies, the most common side effects with Naglazyme (seen in more than 1 patient in 10) were ear pain, dyspnoea (difficulty breathing), abdominal pain and general pain. Patients can also have reactions to the infusion (such as fever, chills, rash and hives). For the full list of all side effects reported with Naglazyme, see the package leaflet.
Naglazyme should not be used in people who may be hypersensitive (allergic) to galsulfase or any of the other ingredients.
The CHMP decided that Naglazyme?s benefits are greater than its risks and recommended that it be given marketing authorisation.
The Committee noted that, although patients under five years of age were not included in the main study of Naglazyme, it is important that they are treated if they have a severe form of MPS VI.
Naglazyme has been authorised under ?exceptional circumstances?. This means that because the disease is rare, it has not been possible to obtain complete information about Naglazyme. Every year, the European Medicines Agency will review any new information that may become available and this summary will be updated as necessary.